AstraZeneca Plc and its Alexion Pharmaceuticals unit have prevailed in a U.S. antitrust lawsuit accusing the companies of using patents and litigation to delay cheaper competition for Soliris, a blockbuster treatment for rare diseases.
U.S. District Judge Brian Murphy granted Alexion’s motion for judgment on the pleadings in a case filed by nonprofit health insurer EmblemHealth, according to a report by Fierce Pharma.
The ruling, issued Monday in federal court in Massachusetts, marks a significant legal victory for AstraZeneca as it manages declining sales of Soliris and shifts patients toward newer treatments in its rare-disease portfolio.
EmblemHealth had alleged that Alexion improperly prolonged Soliris’ market protection through additional patents and legal action against potential biosimilar competitors. The insurer claimed the conduct delayed lower-priced alternatives and caused U.S. purchasers to pay an estimated $2 billion more than they otherwise would have.
Murphy rejected key elements of the insurer’s case, finding that Alexion’s patent enforcement activities were protected from the remaining antitrust allegations, Fierce Pharma reported. The judge also concluded that EmblemHealth lacked the legal standing necessary to pursue its federal antitrust claims and related state-law claims applying similar standards.
Patent Dispute at Center of Case
The litigation focused on Alexion’s efforts to protect Soliris, known generically as eculizumab, after its original patent protections began approaching expiration.
According to Fierce Pharma, Alexion obtained its first Soliris patent in 2002, before the treatment received U.S. regulatory approval in 2007. The patent was originally scheduled to expire in 2019 but was subsequently extended until 2021.
Additional patents secured in 2017 and 2020 extended certain protections through 2027.
Related: AstraZeneca, Bristol Myers Dismiss Merger Talk Speculation
EmblemHealth challenged the legitimacy of those later patents, alleging that Alexion had used improperly obtained intellectual property rights to prevent competing biosimilar medicines from entering the U.S. market sooner.
A central dispute involved Samsung Bioepis, which faced a patent infringement lawsuit from Alexion in January 2024 as it prepared to compete with Soliris.
The companies reached a settlement in August 2024. Under that agreement, Samsung Bioepis withdrew its patent challenges and agreed to postpone the U.S. launch of its competing medicine until April 2025, according to Fierce Pharma.
EmblemHealth argued that the litigation was part of a broader strategy to preserve Alexion’s market position rather than a legitimate effort to defend its intellectual property.
Murphy disagreed with the insurer’s characterization of the lawsuit as baseless. The settlement terms, which benefited Alexion, weakened EmblemHealth’s argument that the underlying patent case had been brought without a reasonable legal foundation, Fierce Pharma reported.
The court consequently found that Alexion’s conduct qualified for protection under a legal principle that generally shields legitimate efforts to petition courts, including certain patent enforcement actions, from antitrust liability.
Biosimilar Competition Reshapes Market
The decision comes as Soliris faces increasing competition from lower-cost biosimilars, which are highly similar versions of complex biological medicines.
Two such products have entered the U.S. market: Amgen’s Bkemv and Epysqli, developed by Samsung Bioepis and marketed in partnership with Teva Pharmaceutical Industries, according to Fierce Pharma.
Soliris is approved to treat several serious conditions, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis and neuromyelitis optica spectrum disorder.
The drug remains a major contributor to AstraZeneca’s revenue, although its commercial importance has diminished as competition increases and the company expands its newer treatment portfolio.
Soliris generated more than $1.8 billion in worldwide sales during 2025, representing a 28% decline from the previous year at constant exchange rates, Fierce Pharma reported, citing AstraZeneca’s financial results.
By comparison, Ultomiris, a newer treatment targeting the same part of the immune system, recorded approximately $4.7 billion in annual sales, an increase of 19% at constant exchange rates.
The contrasting performances reflect AstraZeneca’s continuing transition toward Ultomiris as an important growth driver in its rare-disease business.
AstraZeneca Expands Rare-Disease Portfolio
Beyond the patent dispute, AstraZeneca is pursuing additional opportunities in rare-disease treatments.
According to Fierce Pharma, the company secured regulatory approvals in the United States and European Union this week for Klygefa, a treatment containing gefurulimab, for certain adults with generalized myasthenia gravis.
Unlike Soliris and Ultomiris, which are administered intravenously, Klygefa uses an autoinjector that allows eligible patients or caregivers to administer the medicine at home.
The approval adds another treatment option to AstraZeneca’s portfolio as the company seeks to maintain its position in specialized immune-system disorders.
Source: Fierce Pharma